Vimarsana
Biggest News Aggregation in the World

Informationincluding Patient News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Informationincluding Patient. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Informationincluding Patient Today - Breaking & Trending Today

Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation - Vimarsana News

Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related qua...

Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria - Vimarsana News

Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria

/PRNewswire/ -- In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores...

Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria - Vimarsana News

Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria

/PRNewswire/ -- In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores...